FDA Cites Meta-Analysis To Validate Surrogate Endpoint for Pfizer's Revatio
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee will be asked to support the use of a hemodynamic endpoint in pediatric trials of Pfizer's Revatio (sildenafil).
You may also be interested in...
Surrogate Endpoint For Pediatric PAH Gets Advisory Panel OK, But Validation Process Draws Concern
Pfizer can use a hemodynamic endpoint in pediatric trials of Revatio (sildenafil), but FDA's Cardiovascular and Renal Drugs Advisory Committee expresses enough ambiguity to spoil the precedent.
Surrogate Endpoint For Pediatric PAH Gets Advisory Panel OK, But Validation Process Draws Concern
Pfizer can use a hemodynamic endpoint in pediatric trials of Revatio (sildenafil), but FDA's Cardiovascular and Renal Drugs Advisory Committee expresses enough ambiguity to spoil the precedent.
Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says
Twenty of 33 committee members vote to keep rosiglitazone on the market, with most favoring stronger labeling and restrictions on prescribing.